Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HSDT 
Helius Medical Technologies Inc Class A (HSDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: HSDT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.45% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.06M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.75 | 52 Weeks Range 5.37 - 817.50 | Updated Date 09/17/2025 |
52 Weeks Range 5.37 - 817.50 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12356.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7725.58% |
Management Effectiveness
Return on Assets (TTM) -108.36% | Return on Equity (TTM) -344.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22979148 | Price to Sales(TTM) 81.54 |
Enterprise Value 22979148 | Price to Sales(TTM) 81.54 | ||
Enterprise Value to Revenue 77.9 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 1077260 | Shares Floating 1077246 |
Shares Outstanding 1077260 | Shares Floating 1077246 | ||
Percent Insiders 0.66 | Percent Institutions 1.46 |
Upturn AI SWOT
Helius Medical Technologies Inc Class A
Company Overview
History and Background
Helius Medical Technologies, Inc. (HLS) is a neurotechnology company focused on neurological wellness. It was founded in 2014. The company has developed the PoNS (Portable Neuromodulation Stimulator) device as a potential treatment for neurological symptoms.
Core Business Areas
- Neuromodulation Therapy: Development and commercialization of the PoNS device for neurological conditions. The company's primary focus is on utilizing non-invasive brain stimulation techniques to improve motor function and cognitive abilities.
Leadership and Structure
Dane C. Miller serves as the Chairman of the Board. Anton V. Pottekkatt is the Chief Executive Officer. The company has a board of directors and a management team overseeing operations, research and development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- PoNS (Portable Neuromodulation Stimulator): The PoNS device delivers mild electrical stimulation to the tongue while patients engage in physical therapy exercises. It is intended to improve balance and gait deficits due to mild to moderate symptoms from multiple sclerosis (MS). Helius faces competition from other neurorehabilitation technologies and therapies, including conventional physical therapy and other devices designed to improve balance and motor function. Market share data or revenue specific to PoNS is not readily available due to the company's current stage and limited commercialization but is very low.
Market Dynamics
Industry Overview
The neurorehabilitation market is growing, driven by an aging population and increasing prevalence of neurological disorders such as multiple sclerosis, stroke, and traumatic brain injury. Technological advancements and increasing demand for non-invasive therapies are also contributing to market growth.
Positioning
Helius Medical Technologies is positioned as a company offering a novel neuromodulation therapy for neurological symptoms. Their competitive advantage lies in the unique mechanism of action of the PoNS device and its potential to improve motor function and balance.
Total Addressable Market (TAM)
The total addressable market for neurorehabilitation devices and therapies is estimated to be in the billions of dollars globally. Helius Medical Technologies is positioned to capture a share of this market through commercialization of the PoNS device, however its current positioning and addressable market within the TAM is very limited due to FDA regulation and market awareness.
Upturn SWOT Analysis
Strengths
- Novel neuromodulation technology
- Potential for improved motor function and balance
- FDA authorization for specific indications
- Proprietary technology and intellectual property
Weaknesses
- Limited commercialization experience
- High cost of therapy
- Dependence on regulatory approvals
- Small market share and very low revenue
Opportunities
- Expansion into new indications
- Strategic partnerships with rehabilitation centers
- Increased awareness and adoption of neuromodulation therapies
- International expansion
- Increase in public funding
Threats
- Competition from existing rehabilitation therapies
- Reimbursement challenges
- Adverse clinical trial results
- Regulatory hurdles
- Capital Constraints
Competitors and Market Share
Key Competitors
- NEUR
- TRVN
- BCLI
Competitive Landscape
Helius Medical Technologies faces competition from established rehabilitation therapies and other companies developing neuromodulation devices. Its competitive advantage lies in the unique mechanism of action of the PoNS device and its potential to improve motor function and balance.
Growth Trajectory and Initiatives
Historical Growth: Helius Medical Technologies' historical growth has been limited due to its early stage and dependence on regulatory approvals and commercialization efforts. Revenue has been minimal historically.
Future Projections: Future growth projections for Helius Medical Technologies are uncertain and dependent on the successful commercialization of the PoNS device and expansion into new markets. Analyst estimates vary widely.
Recent Initiatives: Recent strategic initiatives include seeking regulatory approvals, expanding clinical trials, and establishing partnerships with rehabilitation centers.
Summary
Helius Medical Technologies is an early-stage company focused on neuromodulation therapy. It has novel technology that could provide improvement for those with neurological symptoms. However, its limited commercialization experience, high cost of therapy, dependence on regulatory approvals, and small market share are points to watch. Future growth depends on expanding into new markets and successful commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Helius Medical Technologies Inc Class A
Exchange NASDAQ | Headquaters Newtown, PA, United States | ||
IPO Launch date 2014-06-27 | President, CEO & Director Mr. Dane Carl Andreeff | ||
Sector Healthcare | Industry Medical Devices | Full time employees 21 | Website https://heliusmedical.com |
Full time employees 21 | Website https://heliusmedical.com | ||
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.